Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice

Molecular Metabolism

Volumn 3, Issue 2, 2014, Pages 177-190

  Kim, Jun Ho ^a   Meyers, Matthew S ^a   Khuder, Saja S ^b   Abdallah, Simon L ^b   Muturi, Harrison T ^b   Russo, Lucia ^b   Tate, Chandra R ^d   Hevener, Andrea L ^c   Najjar, Sonia M ^b   Leloup, Corinne ^a   Mauvais Jarvis, Franck ^a,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bazedoxifene; Insulin resistance; Menopause; Metabolic syndrome; Tissue selective estrogen complexes; Type 2 diabetes

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTRADIOL; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIRTUIN 1;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG PELLET; ENERGY EXPENDITURE; ENERGY METABOLISM; ENZYME ACTIVITY; FEMALE; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; LIPID DIET; LIPID OXIDATION; LIPID STORAGE; LIVER; METABOLIC DISORDER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; UTERUS GROWTH;

MUS;

EID: 84895796518     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2013.12.009     Document Type: Article

References (58)

1. Carr M.C. The emergence of the metabolic syndrome with menopause. Journal of Clinical Endocrinology and Metabolism 2003, 88(6):2404-2411.
2. Mauvais-Jarvis F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends in Endocrinology and Metabolism 2011, 22(1):24-33.
3. Mauvais-Jarvis F., Clegg D.J., Hevener A.L. The role of estrogens in control of energy balance and glucose homeostasis. Endocrine Reviews 2013, 34(3):309-338.
4. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 2002, 288(3):321-333.
5. Komm B.S., Kharode Y.P., Bodine P.V., Harris H.A., Miller C.P., Lyttle C.R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005, 146(9):3999-4008.
6. Duggan S.T., McKeage K. Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis. Drugs 2011, 71(16):2193-2212.
7. Komm B.S. A new approach to menopausal therapy: the tissue selective estrogen complex. Reproduction Science 2008, 15(10):984-992.
8. Komm B.S., Mirkin S. Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy. International Journal of Women's Health 2012, 4:129-140.
9. Lobo R.A., Pinkerton J.V., Gass M.L., Dorin M.H., Ronkin S., Pickar J.H., et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertility and Sterility 2009, 92(3):1025-1038.
10. Gruber C., Gruber D. Bazedoxifene (Wyeth). Current Opinion in Investigational Drugs 2004, 5(10):1086-1093.
11. Komm B.S., Vlasseros F., Samadfam R., Chouinard L., Smith S.Y. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone 2011, 49(3):376-386.
12. Lindsay R., Gallagher J.C., Kagan R., Pickar J.H., Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertility and Sterility 2009, 92(3):1045-1052.
13. Kharode Y., Bodine P.V., Miller C.P., Lyttle C.R., Komm B.S. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008, 149(12):6084-6091.
14. Pfizer DOF. Duavee USPI September 2013.
15. Rossini M., Lello S., Sblendorio I., Viapiana O., Fracassi E., Adami S., et al. Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture. Drug Design, Development and Therapy 2013, 7:601-610.
16. Pinkerton J.V., Pickar J.H., Racketa J., Mirkin S. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Climacteric 2012, 15(5):411-418.
17. Liu S., Le May C., Wong W.P., Ward R.D., Clegg D.J., Marcelli M., et al. Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 2009, 58(10):2292-2302.
18. Norris A.W., Chen L., Fisher S.J., Szanto I., Ristow M., Jozsi A.C., et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. Journal of Clinical Investigation 2003, 112(4):608-618.
19. Nohara K., Waraich R.S., Liu S., Ferron M., Waget A., Meyers M.S., et al. Developmental androgen excess programs sympathetic tone and adipose tissue dysfunction and predisposes to a cardiometabolic syndrome in female mice. American Journal of Physiology - Endocrinology and Metabolism 2013, 304(12):E1321-E1330.
20. Najjar S.M., Yang Y., Fernstrom M.A., Lee S.J., Deangelis A.M., Rjaily G.A., et al. Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metabolism 2005, 2(1):43-53.
21. Tiano J.P., Delghingaro-Augusto V., Le May C., Liu S., Kaw M.K., Khuder S.S., et al. Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents beta cell failure in rodent models of type 2 diabetes. Journal of Clinical Investigation 2011, 121(8):3331-3342.
22. Kim J.K., Michael M.D., Previs S.F., Peroni O.D., Mauvais-Jarvis F., Neschen S., et al. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. Journal of Clinical Investigation 2000, 105(12):1791-1797.
23. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Annals of the New York Academy of Sciences 1959, 82:420-430.
24. Homma H., Kurachi H., Nishio Y., Takeda T., Yamamoto T., Adachi K., et al. Estrogen suppresses transcription of lipoprotein lipase gene. Existence of a unique estrogen response element on the lipoprotein lipase promoter. Journal of Biological Chemistry 2000, 275(15):11404-11411.
25. Gualillo O., Gonzalez-Juanatey J.R., Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends in Cardiovascular Medicine 2007, 17(8):275-283.
26. Oda N., Imamura S., Fujita T., Uchida Y., Inagaki K., Kakizawa H., et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism 2008, 57(2):268-273.
27. Satoh N., Naruse M., Usui T., Tagami T., Suganami T., Yamada K., et al. Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 2004, 27(10):2488-2490.
28. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436(7049):356-362.
29. Zhang J., Wu Y., Zhang Y., Leroith D., Bernlohr D.A., Chen X. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Molecular Endocrinology 2008, 22(6):1416-1426.
30. Yan Q.W., Yang Q., Mody N., Graham T.E., Hsu C.H., Xu Z., et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007, 56(10):2533-2540.
31. Liu S., Navarro G., Mauvais-Jarvis F. Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice. PLoS One 2010, 5(6):e11302.
32. Volzke H., Schwarz S., Baumeister S.E., Wallaschofski H., Schwahn C., Grabe H.J., et al. Menopausal status and hepatic steatosis in a general female population. Gut 2007, 56(4):594-595.
33. Mauvais-Jarvis P., Vickers CFH W.J. Percutaneous absorption of steroids 1990, Academic Press Inc., New York.
34. Wakil S.J. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 1989, 28(11):4523-4530.
35. Kahn B.B., Alquier T., Carling D., Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 2005, 1(1):15-25.
36. Zhao Y., Dunbar J.D., Kharitonenkov A. FGF21 as a therapeutic reagent. Advances in Experimental Medicine and Biology 2012, 728:214-228.
37. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58(1):250-259.
38. Coskun T., Bina H.A., Schneider M.A., Dunbar J.D., Hu C.C., Chen Y., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149(12):6018-6027.
39. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiological Reviews 2009, 89(1):147-191.
40. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434(7029):113-118.
41. Yonezawa R., Wada T., Matsumoto N., Morita M., Sawakawa K., Ishii Y., et al. Central versus peripheral impact of estradiol on the impaired glucose metabolism in ovariectomized mice on a high-fat diet. American Journal of Physiology - Endocrinology and Metabolism 2012, 303(4):E445-456.
42. Cedars M.I., Judd H.L. Nonoral routes of estrogen administration. Obstetrics and Gynecology Clinics of North America 1987, 14(1):269-298.
43. Arevalo M.A., Santos-Galindo M., Lagunas N., Azcoitia I., Garcia-Segura L.M. Selective estrogen receptor modulators as brain therapeutic agents. Journal of Molecular Endocrinology 2011, 46(1):R1-9.
44. Purushotham A., Schug T.T., Xu Q., Surapureddi S., Guo X., Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metabolism 2009, 9(4):327-338.
45. Aoyama T., Peters J.M., Iritani N., Nakajima T., Furihata K., Hashimoto T., et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). Journal of Biological Chemistry 1998, 273(10):5678-5684.
46. Velasco G., Geelen M.J., Guzman M. Control of hepatic fatty acid oxidation by 5'-AMP-activated protein kinase involves a malonyl-CoA-dependent and a malonyl-CoA-independent mechanism. Archives of Biochemistry and Biophysics 1997, 337(2):169-175.
47. Ribas V., Drew B.G., Soleymani T., Daraei P., Hevener A.L. Skeletal muscle specific ERa deletion is causal for the metabolic syndrome. Endocrine Reviews 2010, 31:S5.
48. Ribas V., Nguyen M.T., Henstridge D.C., Nguyen A.K., Beaven S.W., Watt M.J., et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice. American Journal of Physiology - Endocrinology and Metabolism 2010, 298(2):E304-319.
49. Najjar S.M., Boisclair Y.R., Nabih Z.T., Philippe N., Imai Y., Suzuki Y., et al. Cloning and characterization of a functional promoter of the rat pp120 gene, encoding a substrate of the insulin receptor tyrosine kinase. Journal of Biological Chemistry 1996, 271(15):8809-8817.
50. Pedram A., Razandi M., O'Mahony F., Harvey H., Harvey B.J., Levin E.R. Estrogen reduces lipid content in the liver exclusively from membrane receptor signaling. Science Signaling 2013, 6(276):ra36.
51. Tiano J.P., Mauvais-Jarvis F. Molecular mechanisms of estrogen receptors' suppression of lipogenesis in pancreatic beta-cells. Endocrinology 2012, 153(7):2997-3005.
52. Zhu L., Brown W.C., Cai Q., Krust A., Chambon P., McGuinness O.P., et al. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes 2013, 62(2):424-434.
53. Riant E., Waget A., Cogo H., Arnal J.F., Burcelin R., Gourdy P. Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 2009, 150(5):2109-2117.
54. Bryzgalova G., Gao H., Ahren B., Zierath J.R., Galuska D., Steiler T.L., et al. Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia 2006, 49(3):588-597.
55. Puah J.A., Bailey C.J. Effect of ovarian hormones on glucose metabolism in mouse soleus muscle. Endocrinology 1985, 117(4):1336-1340.
56. Guo H., Zhang Y., Brockman D.A., Hahn W., Bernlohr D.A., Chen X. Lipocalin 2 deficiency alters estradiol production and estrogen receptor signaling in female mice. Endocrinology 2012, 153(3):1183-1193.
57. Yang J., Bielenberg D.R., Rodig S.J., Doiron R., Clifton M.C., Kung A.L., et al. Lipocalin 2 promotes breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(10):3913-3918.
58. Shi H., Gu Y., Yang J., Xu L., Mi W., Yu W. Lipocalin 2 promotes lung metastasis of murine breast cancer cells. Journal of Experimental and Clinical Cancer Research 2008, 27:83.